However, although EGFR-TKI alleviated proteinuria and kidney injury in crescentic glomerulonephritis [46], in clinical trials, the combination of VEGFR2 monoclonal antibody ramucirumab and EGFR inhibitor erlotinib resulted in the increased incidence of proteinuria compared to ramucirumab alone [5]. The gene discussed is EGFR; the disease is crescentic glomerulonephritis.